Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Mollica L, Tassi E, Copaloni A, De Simone I, Barouni RM, De Giorgi S, Pagano A, Lampertico G, Noviello M, Ferrara M, Garavaglia B, Guarnieri S, Bulotta A, Viganò MG, Ogliari FR, Oresti S, Damiano G, Russo V, Riva ST, Nuccio A, Salomone F, Venanzi FM, Passaretti F, Papotto L, Zotti D, Di Lello A, Carbone C, Bria E, Sistigu A, Musella M, Verlicchi A, Ulivi P, Genova C, Tagliamento M, Ferlazzo G, Russo GL, Brambilla M, Pasello G, Mandruzzato S, Corbo V, Pilotto S, De Sanctis F, Gelibter A, Piconese S, Tiseo M, Mazzaschi G, Pluchino M, Cappuzzo F, Minuti G, Landi L, Nisticò P, Arasanz H, Labiano I, Mezquita L, Pascal M, Lavaud P, Chaput N, Grisanti S, Bettini AC, Cortinovis DL, Galli G, La Verde N, Panni S, Liguigli W, Petrelli F, Santo A, Signorelli D, Tomasello G, Toschi L, Catania C, Fazio GRD, Anselmi E, De Giglio A, Ardizzoni A, Bennati C, Indraccolo S, Genua M, Ostuni R, Bellone M, Clementi N, Esposito A, De Cobelli F, Palumbo D, Damascelli A, Prato F, De Pretis S, Lazarević D, Ruggiero E, Ponzoni M, Arrigoni G, Pedica F, Veronesi G, Colombo MP, Rulli E, Torri V, Sacco M, Garassino MC, Besse B, Reni M, Cascinu S, Ciceri F, Bonini C, Sangaletti S, Ferrara R

Open source

DOI: 10.1016/j.cllc.2026.08.005
Published: 2026 Aug 13
Container: Clinical lung cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.08.005,
  title = {Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50\% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.},
  author = {Mollica L and Tassi E and Copaloni A and De Simone I and Barouni RM and De Giorgi S and Pagano A and Lampertico G and Noviello M and Ferrara M and Garavaglia B and Guarnieri S and Bulotta A and Viganò MG and Ogliari FR and Oresti S and Damiano G and Russo V and Riva ST and Nuccio A and Salomone F and Venanzi FM and Passaretti F and Papotto L and Zotti D and Di Lello A and Carbone C and Bria E and Sistigu A and Musella M and Verlicchi A and Ulivi P and Genova C and Tagliamento M and Ferlazzo G and Russo GL and Brambilla M and Pasello G and Mandruzzato S and Corbo V and Pilotto S and De Sanctis F and Gelibter A and Piconese S and Tiseo M and Mazzaschi G and Pluchino M and Cappuzzo F and Minuti G and Landi L and Nisticò P and Arasanz H and Labiano I and Mezquita L and Pascal M and Lavaud P and Chaput N and Grisanti S and Bettini AC and Cortinovis DL and Galli G and La Verde N and Panni S and Liguigli W and Petrelli F and Santo A and Signorelli D and Tomasello G and Toschi L and Catania C and Fazio GRD and Anselmi E and De Giglio A and Ardizzoni A and Bennati C and Indraccolo S and Genua M and Ostuni R and Bellone M and Clementi N and Esposito A and De Cobelli F and Palumbo D and Damascelli A and Prato F and De Pretis S and Lazarević D and Ruggiero E and Ponzoni M and Arrigoni G and Pedica F and Veronesi G and Colombo MP and Rulli E and Torri V and Sacco M and Garassino MC and Besse B and Reni M and Cascinu S and Ciceri F and Bonini C and Sangaletti S and Ferrara R},
  year = {2026},
  journal = {Clinical lung cancer},
  doi = {10.1016/j.cllc.2026.08.005},
  url = {https://doi.org/10.1016/j.cllc.2026.08.005}
}

RIS

TY  - JOUR
TI  - Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.
AU  - Mollica L
AU  - Tassi E
AU  - Copaloni A
AU  - De Simone I
AU  - Barouni RM
AU  - De Giorgi S
AU  - Pagano A
AU  - Lampertico G
AU  - Noviello M
AU  - Ferrara M
AU  - Garavaglia B
AU  - Guarnieri S
AU  - Bulotta A
AU  - Viganò MG
AU  - Ogliari FR
AU  - Oresti S
AU  - Damiano G
AU  - Russo V
AU  - Riva ST
AU  - Nuccio A
AU  - Salomone F
AU  - Venanzi FM
AU  - Passaretti F
AU  - Papotto L
AU  - Zotti D
AU  - Di Lello A
AU  - Carbone C
AU  - Bria E
AU  - Sistigu A
AU  - Musella M
AU  - Verlicchi A
AU  - Ulivi P
AU  - Genova C
AU  - Tagliamento M
AU  - Ferlazzo G
AU  - Russo GL
AU  - Brambilla M
AU  - Pasello G
AU  - Mandruzzato S
AU  - Corbo V
AU  - Pilotto S
AU  - De Sanctis F
AU  - Gelibter A
AU  - Piconese S
AU  - Tiseo M
AU  - Mazzaschi G
AU  - Pluchino M
AU  - Cappuzzo F
AU  - Minuti G
AU  - Landi L
AU  - Nisticò P
AU  - Arasanz H
AU  - Labiano I
AU  - Mezquita L
AU  - Pascal M
AU  - Lavaud P
AU  - Chaput N
AU  - Grisanti S
AU  - Bettini AC
AU  - Cortinovis DL
AU  - Galli G
AU  - La Verde N
AU  - Panni S
AU  - Liguigli W
AU  - Petrelli F
AU  - Santo A
AU  - Signorelli D
AU  - Tomasello G
AU  - Toschi L
AU  - Catania C
AU  - Fazio GRD
AU  - Anselmi E
AU  - De Giglio A
AU  - Ardizzoni A
AU  - Bennati C
AU  - Indraccolo S
AU  - Genua M
AU  - Ostuni R
AU  - Bellone M
AU  - Clementi N
AU  - Esposito A
AU  - De Cobelli F
AU  - Palumbo D
AU  - Damascelli A
AU  - Prato F
AU  - De Pretis S
AU  - Lazarević D
AU  - Ruggiero E
AU  - Ponzoni M
AU  - Arrigoni G
AU  - Pedica F
AU  - Veronesi G
AU  - Colombo MP
AU  - Rulli E
AU  - Torri V
AU  - Sacco M
AU  - Garassino MC
AU  - Besse B
AU  - Reni M
AU  - Cascinu S
AU  - Ciceri F
AU  - Bonini C
AU  - Sangaletti S
AU  - Ferrara R
PY  - 2026
JO  - Clinical lung cancer
DO  - 10.1016/j.cllc.2026.08.005
UR  - https://doi.org/10.1016/j.cllc.2026.08.005
ER  -

APA

L, M., E, T., A, C., I, D. S., RM, B., S, D. G., A, P., G, L., M, N., M, F., B, G., S, G., A, B., MG, V., FR, O., S, O., G, D., V, R., ST, R., A, N., F, S., FM, V., F, P., L, P., D, Z., A, D. L., C, C., E, B., A, S., M, M., A, V., P, U., C, G., M, T., G, F., GL, R., M, B., G, P., S, M., V, C., S, P., F, D. S., A, G., S, P., M, T., G, M., M, P., F, C., G, M., L, L., P, N., H, A., I, L., L, M., M, P., P, L., N, C., S, G., AC, B., DL, C., G, G., N, L. V., S, P., W, L., F, P., A, S., D, S., G, T., L, T., C, C., GRD, F., E, A., A, D. G., A, A., C, B., S, I., M, G., R, O., M, B., N, C., A, E., F, D. C., D, P., A, D., F, P., S, D. P., D, L., E, R., M, P., G, A., F, P., G, V., MP, C., E, R., V, T., M, S., MC, G., B, B., M, R., S, C., F, C., C, B., S, S., & R, F. (2026). Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2026.08.005

Source records

pubmed · retrieved 2026-09-25T04:51:34.605Z
europe-pmc · retrieved 2026-09-25T04:51:34.645Z